As per the
Parkinson’s Disease Foundation, about 7–10 million people suffer from Parkinson’s
disease, globally. In the U.S., each year, 60,000 new cases of Parkinson’s
disease are reported. Further, epilepsy is one of the most common neurological
disorders and affects people of all age groups.
The World
Health Organization said that about 50 million people across the world suffer
from epilepsy, and about 2.4 million people are diagnosed with the condition
every year. Chronic pain is associated with these diseases and many other
conditions and may even be a result of injuries, which greatly affects the way
of life. In a study conducted by the International Association for the Study of
Pain, it was reported that about 2.8% of the total diabetic population suffered
from peripheral neuropathic pain in 2000, and it is predicted to grow to 4.4%
by 2030.
Download
Sample of This Research Report:
The demand
for these devices was the highest in North America among all the regions,
namely Asia, Europe, and Rest of the World. This was attributed to the surging
geriatric population and the growing incidence of neurological disorders in the
region. Further, the popularity of minimally invasive treatment and the
increasing research & development activities in the development of
innovative neurostimulation devices have been instrumental in driving the
regional market forward. The neurostimulation device market is expected to register a 12.9% CAGR
during 2016–2022.
Chronic
pains more commonly affect nerves, bones, and the back. These pains can be
debilitating, and to treat them, neurostimulation devices are used. These
devices work by generating mild electric signals that reach the brain faster
than pain signals, and trick the patient into feeling the tingling sensation
instead of pain, they block pain signals before they reach the brain, thereby
providing relief to patients. Some common pain management devices available in
the neurostimulation device market are peripheral nerve stimulation device and
SCS device.
